MedTrace Logo

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

NCT04831047 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2023-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes.

Conditions

  • Ptosis, Eyelid
  • Conjunctiva Inflamed
  • Eye Manifestations

Interventions

DRUG

Oxymetazoline hydrochloride 0.1% ophthalmic solution

One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.

DRUG

Placebo

One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Wendy W. Lee, MD · University of Miami Bascom Palmer Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-08
Primary Completion
2022-04-01
Completion
2022-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04831047 on ClinicalTrials.gov